［1］汤钊猷.原发性肝癌的研究进展［J］. 中国肿瘤临床, 1998， 25: 133-142.
［2］NKontchou G， Mahamoudi A， Aout M， et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis［J］. Hepatology， 2009， 50: 1475-1483.
［3］翟博， 李晓燕， 刘晟， 等. 膈顶部原发性肝癌的射频消融［J］. 介入放射学杂志， 2009， 18: 357-361.
［4］Yang B, Zou J, Xia J, et al. Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous adiofrequency ablation［J］. Eur J Radiol, 2011， 79： 196-200.
［5］Peng ZW， Zhang YJ, Chen MS, et al. Radiofrequency ablationas first-line treatment for small solitary hepatocellular carcinoma： long-term results ［J］. Eur J Surg Oncol, 2010, 36： 1054-1060.
［6］高恒军, 陈敏山. RFA治疗肝癌的选择与其联合治疗方式［J］. 中华肝脏病杂志, 2012, 20： 245-247.
［7］吴沛宏， 张福君， 赵明， 等. 肝动脉栓塞化疗联合CT导向RFA术治疗中、晚期肝癌的评价［J］. 中华放射学杂志， 2003， 37: 901-904.
［8］Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial［J］. Radiology, 2012, 262: 689-700.
［9］Peng ZW， Zhang YJ， Chen MS， et al. Risk factors of survival afterpercutaneous radiofrequency ablation of hepatocellular carcinoma［J］. Surg Oncol， 2008, 17: 23-31.
［10］Cui Y， Zhou LY， Ji M， et al. Percutaneous radiofrequency ablation therapy for hepatic malignancies in 114 patients［J］. Chin J Mod Med， 2004， 14: 129-131.